Johnson & Johnson announces new icotrokinra data from Phase 3 program
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...
Johnson & Johnson axes late-stage program for depression therapy
Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...
Johnson & Johnson Pitches Final Arguments to Approve $10B Talc Bankruptcy Plan
In Friday's hearing, which lasted 10 hours, U.S. Bankruptcy Judge Christopher Lopez heard closing arguments in Johnson & ...
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...